Wolfram Samlowski

18PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyImmunogenetics (incl. genetic immunology)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jul 28, 2026
Incidence and Clinical Impact of Endocrinopathy Following First-Line Nivolumab-Plus-Relatlimab Therapy for Metastatic Melanoma.

|May 19, 2026
Durable remission of metastatic myxoid liposarcoma following the cautious addition of pembrolizumab to ongoing pazopanib treatment: A case report.

|May 04, 2026
Reply to Correa et al. Comment on "Rivas et al. Unexpectedly Low Rate of Metastasis and Death Among Patients Treated for Uveal Melanoma with Brachytherapy, Vitrectomy, and Silicone Oil. Cancers 2025, 17, 2683".

|Aug 28, 2025
Unexpectedly Low Rate of Metastasis and Death Among Patients Treated for Uveal Melanoma with Brachytherapy, Vitrectomy, and Silicone Oil.

Axel Rivas, Wolfram Samlowski, Tara A McCannel

|Mar 13, 2025
Effectiveness and Toxicity of Cemiplimab Therapy for Advanced Cutaneous Squamous Cell Skin Cancer in a Community Oncology Practice.

Tina Fung, Wolfram Samlowski, Raul Meoz

|Feb 11, 2025
Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice.

Claire Victoria Ong, Wolfram Samlowski

Pageof 3

Frequent Collaborators

2 joint publications

Axel Rivas

1 joint publications

Ruby Lopez-Flores

1 joint publications

Sandip P Patel

1 joint publications

Megan Othus